Outlook Therapeutics (OTLK) Total Liabilities (2015 - 2026)

Outlook Therapeutics (OTLK) has 12 years of Total Liabilities data on file, last reported at $50.9 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $50.9 million, down 1.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $50.9 million (down 1.26% YoY), and the FY2025 annual result was $50.8 million, down 50.17% from the prior year.
• Total Liabilities eased to $50.9 million in Q1 2026 per OTLK's latest filing, from $56.8 million in the prior quarter.
• Over five years, Total Liabilities peaked at $193.3 million in Q1 2024 and troughed at $18.5 million in Q2 2022.
• A 5-year average of $62.7 million and a median of $50.8 million in 2025 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities surged 343.92% in 2024, then slumped 73.33% in 2025.
• A 5-year view of Total Liabilities shows it stood at $46.9 million in 2022, then dropped by 1.92% to $46.0 million in 2023, then jumped by 46.21% to $67.3 million in 2024, then fell by 15.62% to $56.8 million in 2025, then declined by 10.39% to $50.9 million in 2026.
• Business Quant data shows OTLK's Total Liabilities at $50.9 million in Q1 2026, $56.8 million in Q4 2025, and $50.8 million in Q3 2025.